|
Ovid Therapeutics Inc (OVID) Ovid Therapeutics is a biopharmaceutical company focus on reducing seizures and epilepsies and seizure-related neurological disorders. Co.'s pipeline has produced two epilepsy programs with potential mechanisms of action (MoA), and one epilepsy program with a potential MoA. These programs include soticlestat, which is a cholesterol 24 hydroxylase inhibitor. OV350 is a potential direct activator of the K-Cl co-transporter (KCC2) transporter, and is one among many KCC2 activator compounds in its portfolio. OV329 is a GABA aminotransferase inhibitor. Co.'s genetic research programs include OV815, which focuses on the mutations associated with KIF1A-associated neurological disorder.
|
|